Regenerative medicine developer Biostage cancels Nasdaq uplisting, public offering Posted on February 3, 2023 By Charlielikes Stock Market
Regenerative therapy developer Biostage files for Nasdaq uplisting, $6M offering Posted on October 28, 2022 By Charlielikes Stock Market